P670: EARLY CYTOGENETIC OR MOLECULAR LANDMARK RESPONSE TO PONATINIB TREATMENT PREDICTS OUTCOMES IN HEAVILY PRETREATED PATIENTS WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA IN PACE: 5-YEAR DATA

• Martin C. Müller,
• Jorge Cortes,
• Charles Chuah,
• Daniel Deangelo,
• Michael Deininger,
• François Guilhot,
• Timothy Hughes,
• Franck Emmanuel Nicolini,
• Javier Pinilla-Ibarz,
• Delphine Rea,
• Gianantonio Rosti,
• Neil P. Shah,
• Moshe Talpaz,
• Vickie Lu,
• Thihan Padukkavidana,
• Hagop Kantarjian

Affiliations

Martin C. Müller

1 Institute for Hematology and Oncology (IHO GmbH), Mannheim, Germany

Jorge Cortes

2 Georgia Cancer Center, Augusta, United States

Charles Chuah

3 Singapore General Hospital, Duke-NUS Medical School, Singapore, Singapore

Daniel Deangelo

4 Dana-Farber Cancer Institute, Boston, United States

Michael Deininger

5 Versiti Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI, United States

François Guilhot

6 INSERM Centre d’Investigation Clinique 1402, CHU de Poitiers, Poitiers, France

Timothy Hughes

7 University of Adelaide and South Australian Health and Medical Research Institute, Adelaide, Australia

Franck Emmanuel Nicolini

8 Centre Léon Bérard, Lyon, France

Javier Pinilla-Ibarz

9 H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, United States

Delphine Rea

10 Hôpital Saint-Louis, Paris, France

Gianantonio Rosti

11 IRST/IRCCS “Dino Amadori”, Meldola (FC), Italy

Neil P. Shah

12 University of California San Francisco, San Francisco, CA, United States

Moshe Talpaz

13 Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, United States

Vickie Lu

14 Takeda Development Center Americas, Inc., Lexington, MA, United States

Thihan Padukkavidana

14 Takeda Development Center Americas, Inc., Lexington, MA, United States

Hagop Kantarjian

15 The University of Texas MD Anderson Cancer Center, Houston, TX, United States